Anti-Malarial Drugs Market share, Size and Insights with 4.4% CAGR during the Forecast period 2019-2027

 

Anti-Malarial Drugs Market

Malaria has ravaged the world's tropical regions, including Africa and Asia, Central and South America, Haiti and the Dominican Republic, sections of the Middle East, and Pacific islands. One of the factors driving market expansion is the rise in incidence of traveler's malaria. Every year, thousands of individuals travel to malaria-affected areas across the world, increasing the risk of infection. According to the Global Health, Division of Parasitic Diseases and Malaria, and (CDC), around 2,000 cases of malaria are identified in the United States each year. To avoid the increasing number of patient pool and to reduce the risk of traveler’s malaria, travelers are being advised by the regulatory authorities to have the antimalarial medicines with them.

Increasing R&D initiatives to create innovative treatment approaches, as well as cooperation among major companies, are projected to fuel market growth. Medicines for Malaria Venture (MMV) is a non-profit public-private collaboration founded in 1999 with the goal of reducing the burden of malaria in disease-endemic countries via the development of innovative treatment alternatives. Many major pharmaceutical firms have been working with MMV to develop innovative drug entities for the treatment of malaria. For example, in December 2019, Ipca Laboratories announced a collaborative agreement with Medicines for Malaria Venture to develop Atoguanil, a new antimalarial co-formulation composed of atovaquone and proguanil.

According to Coherent Market Insights, The global Anti Malarial Drugs Market was valued at US$ 839.1 million in 2019 and is expected to exhibit a CAGR of 4.4% during the forecast period (2019–2027).

Furthermore, increased regional government funding is considerably contributing to the expansion of the worldwide anti-malaria Drugs market. These funds are anticipated to provide opportunities for research organisations such as Medicines for Malaria Venture to continue research investigations for possible malaria lead candidates. For example, in November 2017, the United States Agency for International Development (USAID) granted Medicines for Malaria Venture US$ 9 million for a 5-year period to conduct three projects: a pharmacovigilance study of Pyramax (pyronaridine-artesunate), a SERC Phase III study to develop a single-exposure radical cure, and a study of the efficacy of DSM265, a potential single-exposure radical cure.

Adverse effects and dangers connected with anti-malarial Drugs are projected to impede the growth of the worldwide anti-malarial pharmaceuticals market. The majority of anti-malaria Drugs have significant side effects, which is predicted to reduce demand for these drugs. Mefloquine, for example, can cause nausea, vomiting, stomach discomfort, headache, sleeplessness, and vivid nightmares. Other adverse effects of Mefloquine include dizziness, loss of balance, extreme anxiety, sadness, restlessness, disorientation, and others. These obstacles are projected to stifle market expansion.

Competitive Landscape of anti-malarial drugs market includes Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc.